Related Experiment Video

Updated: Apr 28, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K

Possible association of IL-4 VNTR polymorphism with susceptibility to preeclampsia

Saeedeh Salimi1, Milad Mohammadoo-Khorasani1, Minoo Yaghmaei2

  • 1Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan 9816743111, Iran ; Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan 9816743111, Iran.

Biomed Research International
|May 31, 2014
PubMed

Insights

Interleukin-4 VNTR polymorphism significantly increases preeclampsia risk in Iranian women. Carriage of the IL-4 VNTR RP2 allele is associated with higher susceptibility to this pregnancy-specific disorder.

Area of Science:

  • Obstetrics and Gynecology
  • Immunogenetics
  • Reproductive Medicine

Background:

  • Preeclampsia (PE) is a significant cause of maternal mortality and morbidity worldwide.
  • Cytokines are increasingly recognized for their role in PE pathogenesis.
  • Interleukin-4 (IL-4) gene polymorphism, specifically VNTR, is a potential factor influencing PE risk.

Purpose of the Study:

  • To investigate the association between Interleukin-4 (IL-4) VNTR polymorphism and preeclampsia susceptibility in the Iranian population.
  • To be the first study to examine this genetic link in this demographic.

Main Methods:

  • Polymerase chain reaction (PCR) was used to genotype the IL-4 VNTR polymorphism.
  • The study included 192 women diagnosed with preeclampsia and 186 healthy pregnant women as controls.

Main Results:

  • A significant association was found between IL-4 VNTR polymorphism and increased preeclampsia risk.
  • Carriage of the RP2/RP1 genotype showed a 2.8-fold increased risk (OR, 2.8 [95% CI, 1.7 to 8.8]; P = 0.0001).
  • The RP2/RP2 genotype also demonstrated a significant association with preeclampsia (P = 0.002), indicating higher susceptibility with the RP2 allele.

Conclusions:

  • The VNTR polymorphism of the Interleukin-4 gene is significantly associated with preeclampsia susceptibility in the Iranian population.
  • The presence of the IL-4 VNTR RP2 allele is linked to an elevated risk of developing preeclampsia.

More Related Videos

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.4K
Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface07:51

Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface

Published on: May 21, 2015

17.0K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157